早期非小细胞肺癌患者血清巨噬细胞抑制因子-1、趋化素与临床病理特征及预后的关系  

Relationship between Serum Macrophage Inhibitor-1, Chemokine and Clinicopathological Features and Prognosis in Patients with Early Non-small Cell Lung Cancer

作　　者：吕蒙 王昂[2] 王杰 鄢文[2] 尤长宣[1] LV Meng;WANG Ang;WANG Jie;YAN Wen;YOU Chang-xuan(Department of Oncology,Huiqiao Medical Center,Nanfang Hospital of Southern Medical University,Guangzhou,Guangdong,510000,China;First Ward of Oncology,Second People's Hospital of Guangdong Province,Guangzhou,Guangdong,510000,China;Department of Radiotherapy,Second People's Hospital of Guangdong Province,Guangzhou,Guangdong,510000,China)

机构地区：[1]南方医科大学南方医院惠侨医疗中心肿瘤科,广东广州510000 [2]广东省第二人民医院肿瘤一区,广东广州510000 [3]广东省第二人民医院放疗科,广东广州510000

出　　处：《现代生物医学进展》2019年第21期4103-4107,共5页Progress in Modern Biomedicine

基　　金：广东省科技计划项目(2017B090901067)

摘　　要：目的:探讨早期非小细胞肺癌(NSCLC)患者血清巨噬细胞抑制因子-1(MIC-1)、趋化素(chemerin)水平与临床病理特征及预后的关系。方法:选择72例NSCLC患者(NSCLC组)、53例肺良性疾病患者(良性组)、50例体检健康人群(对照组),分别检测血清MIC-1、chemerin水平,分析血清MIC-1、chemerin水平与NSCLC患者临床病理参数的关系。Kaplan-Meier法分析不同血清MIC-1、chemerin水平NSCLC患者生存时间的差异,COX比例风险回归分析血清MIC-1、chemerin水平与NSCLC患者预后的关系。结果:NSCLC组患者血清MIC-1、chemerin水平高于良性组和对照组(P<0.05)。血清MIC-1水平与NSCLC患者年龄、目前吸烟、肿瘤直径、TNM分期、分化程度、复发或转移、生存状态有关(P<0.05),chemerin水平与NSCLC患者目前吸烟、TNM分期、复发或转移、生存状态有关(P<0.05)。高MIC-1水平患者生存率低于低MIC-1水平患者(P<0.05),高chemerin水平患者生存率低于低chemerin水平患者(P<0.05)。COX比例风险回归分析结果显示:血清MIC-1、chemerin、TNM分期与NSCLC不良预后独立相关。结论:血清MIC-1、chemerin水平与NSCLC患者部分临床病理参数和预后相关,可作为早期NSCLC患者预后预测的潜在指标。Objective: To investigate the relationship between serum level of macrophage inhibitory factor-1(MIC-1) and chemerin and clinicopathological features and prognosis in patients with early non-small cell lung cancer(NSCLC). Methods: 72 patients with NSCLC(NSCLC group), 53 patients with benign pulmonary diseases(benign group) and 50 healthy people(control group) were selected. Serum MIC-1 and chemerin levels were detected respectively. The relationship between serum MIC-1 and chemerin levels and clinicopathological parameters of NSCLC patients was analyzed. The survival time of NSCLC patients with different serum levels of MIC-1 and Chemerin was analyzed by Kaplan-Meier method. The relationship between serum levels of MIC-1 and chemerin and the prognosis of NSCLC patients was analyzed by COX proportional risk regression. Results: The serum MIC-1 and chemerin levels in NSCLC group were higher than those in benign group(P<0.05). Serum MIC-1 level was correlated with age, current smoking, tumor diameter, TNM stage, differentiation degree, recurrence or metastasis, survival status of NSCLC patients(P<0.05), and chemerin level was correlated with current smoking, TNM stage, recurrence or metastasis and survival status of NSCLC patients(P<0.05). The survival rate of patients with high MIC-1 level was lower than that of patients with low MIC-1 level(P<0.05), and survival rate of patients with high chemerin level was lower than that of patients with low chemerin level(P<0.05). COX proportional risk regression analysis showed that serum MIC-1, chemerin and TNM stage levels were independently associated with poor prognosis of NSCLC. Conclusion: Serum MIC-1 and chemerin levels are correlated with some clinicopathological parameters and prognosis of NSCLC patients, and they can be used as potential prognostic indicators for early NSCLC patients.

关 键 词：非小细胞肺癌 巨噬细胞抑制因子-1 趋化素 病理特征 预后 

分 类 号：R734.2[医药卫生—肿瘤]